Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis-Reference-Cited by-同舟云学术

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis

Published:2023-11 Issue:11 Volume:5 Page:100874
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

Fuchs Claudia D.^ORCID,Sroda Natalie^ORCID,Scharnagl Hubert^ORCID,Gupta Ruchi,Minto Wesley,Stojakovic Tatjana,Liles John T.,Budas Grant,Hollenback David^ORCID,Trauner Michael

Funder

Gilead Sciences

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Immunology and Allergy,Internal Medicine

Reference39 articles.

1. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study;de Vries;Liver Int,2017

2. Pathogenesis of primary sclerosing cholangitis;Pollheimer;Best Pract Res Clin Gastroenterol,2011

3. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice;Pawlak;Hepatology,2014

4. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease;Pawlak;J Hepatol,2015

5. Farnesoid X receptor agonists for primary biliary cirrhosis;Lindor;Curr Opin Gastroenterol,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of FXR in the development of NAFLD and intervention strategies of small molecules;Archives of Biochemistry and Biophysics;2024-07

2. Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions;Hepatology Research;2024-01-22

3. Targeting bile salt homeostasis in biliary diseases;Current Opinion in Gastroenterology;2024-01-10